Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-09-25
|
|
Crohn's Disease |
|
Enterome Bioscience (France) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2016-09-24
|
ALN-GO1 |
primary hyperoxaluria type 1 (PH1) |
1-2 |
Alnylam Pharmaceuticals (USA - MA) |
Rare diseases - Genetic diseases |
2016-09-23
|
Zykadia® - LDK378 (ceritinib) |
patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) |
3 |
Novartis (Switzerland) |
Cancer - Oncology |
2016-09-23
|
ROR?t inverse agonists |
|
preclinical |
Genfit (France) |
Immunological diseases |
2016-09-22
|
ISIS-APO(a) Rx, now IONIS-APO(a) Rx |
high lipoprotein(a), or Lp(a) |
1 |
Isis Pharmaceuticals, now Ionis Pharmaceuticals (USA - CA) Akcea Therapeutics (USA - CA) |
Cardiovascular diseases - Metabolic diseases |
2016-09-21
|
autologous CD34+ haematopoietic stem cells transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene |
adenosine deaminase deficient severe combined immunodeficiency (ADA-SCID) |
|
Orchard Therapeutics (UK) |
Rare diseases - Genetic diseases |
2016-09-21
|
GS-5745 |
ulcerative colitis |
2-3 |
Gilead Sciences (USA - CA) |
Autoimmune diseases – Inflammatory diseases - Digestive diseases |
2016-09-21
|
CD201 |
multi-drug resistant (MDR) bacterial infections, including those caused by MCR-1 resistant pathogens |
|
Cidara Therapeutics (USA - CA) |
Infectious diseases |
2016-09-20
|
BioChaperone® Combo |
type 2 diabetes |
1b |
Adocia (France) |
Metabolic diseases |
2016-09-20
|
BL-8040 in combination with Keytruda® (pembrolizumab) |
pancreatic cancer |
2a |
Merck&Co (USA - NJ) BiolineRx (Israel) |
Cancer - Oncology |
2016-09-20
|
noninvasive NASH diagnostic based on miRNAs |
NASH (non-alcoholic steatohepatitis) |
|
Genfit (France) |
Metabolic diseases - Liver diseases - Hepatic diseases |
2016-09-20
|
Repatha® (evolocumab) |
coronary artery disease |
3 |
Amgen (USA - CA) |
Cardiovascular diseases |
2016-09-19
|
SGN-CD123A |
relapsed or refractory acute myeloid leukemia |
1 |
Seattle Genetics (USA - WA) |
Cancer - Oncology |
2016-09-19
|
pridopidine |
motor impairment in patients with Huntington's disease |
2 |
Teva Pharmaceuticals (Israel) |
Neurodegenerative diseases - Rare diseases - Genetic diseases |
2016-09-19
|
FCX-007 |
recessive dystrophic epidermolysis bullosa |
1-2 |
Fibrocell Technologies (USA - PA) Intrexon (USA - MD) |
Rare diseases - Genetic diseases - Dermatological diseases |
2016-09-19
|
foliglurax (PXT002331) |
Parkinson's disease |
1 |
Prexton Therapeutics (Switzerland) |
Neurological diseases - CNS diseases |
2016-09-17
|
siponimod (BAF312) |
secondary progressive multiple sclerosis |
3 |
Novartis (Switzerland) |
Autoimmune diseases - Neurodegenerative diseases |
2016-09-16
|
semaglutide |
type 2 diabetes |
3 |
Novo Nordisk (Denmark) |
Metabolic diseases |
2016-09-16
|
PF-06438179 (infliximab-Pfizer) |
moderate to severely active rheumatoid arthritis |
3 |
Pfizer (USA - NY) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2016-09-16
|
ozanimod |
relapsing multiple sclerosis |
2 |
Celgene (USA - NJ) |
Neurodegenerative diseases - Autoimmune diseases |